NY-ESO-1 expression in sarcomas

NY-ESO-1 (CTAG 1B) is highly expressed in the majority of synovial sarcomas and myxoid/round cell liposarcomas as well as in a subset of melanomas, but only rarely in other mesenchymal tumors. This points to a potential for using NY-ESO-1 in the differential diagnosis of these lesions. Furthermore, promising results have been obtained in clinical trials testing NY-ESO-1-targeted immunotherapy in subsets of melanoma and synovial sarcoma patients.

• Publication year

  2012

• Venue

  Oncoimmunology

• Publication date

  2012-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.4161/onci.21059PMID 23243610PMCID 3518519
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• NY‐ESO‐1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma

  2012cited by this paper
• NY-ESO-1 expression in synovial sarcoma and other mesenchymal tumors: significance for NY-ESO-1-based targeted therapy and differential diagnosis

  2012cited by this paper
• Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.

  2011cited by this paper
• Myxoid/round cell and pleomorphic liposarcomas

  2007cited by this paper
• Expression of multiple cancer-testis antigen genes in gastrointestinal and breast carcinomas

  2001cited by this paper
• Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen ny‐eso‐1 but not mage‐a1 or ct7

  2001cited by this paper
• Identification of CD4+ T Cell Epitopes from NY-ESO-1 Presented by HLA-DR Molecules

  2000cited by this paper
• Cancer immunotherapy in clinical oncology

  2000cited by this paper
• A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening.

  1997cited by this paper

• Review of Adoptive Cellular Therapies for the Treatment of Sarcoma

  2025cites this paper
• Preclinical Development of Costimulatory Switch Protein (CSP)-Armored NY-ESO-1/LAGE-1a-Specific TCR-T Cells for Therapy of Hard-to-Treat PD-L1-Positive Solid Tumors

  2025cites this paper
• Stabilized iRGD modification enhances NY-ESO-1 TCR-T infiltration in solid tumors and synergizes with PD-1 blockade

  2025cites this paper
• Synovial sarcoma: A case report of first presentation at penoscrotal junction

  2025cites this paper
• NY‐ESO‐1 antigen: A promising frontier in cancer immunotherapy

  2024cites this paper
• Synovial Sarcoma of Testis: a Rare Tumour at an Uncommon Site—A Case Report

  2024cites this paper
• Potentially actionable targets in synovial sarcoma: A tissue microarray study

  2024cites this paper
• Advances in immunology and immunotherapy for mesenchymal gastrointestinal cancers

  2023cites this paper
• Synovial sarcoma: characteristics, challenges, and evolving therapeutic strategies

  2023cites this paper
• Treatment at Relapse for Synovial Sarcoma of Children, Adolescents and Young Adults: From the State of Art to Future Clinical Perspectives

  2023cites this paper
• Emerging Trends in Immunotherapy for Adult Sarcomas

  2023cites this paper
• Biomarker correlates with response to NY-ESO-1 TCR T cells in patients with synovial sarcoma

  2022cites this paper
• What’s the latest with investigational drugs for soft tissue sarcoma?

  2022cites this paper
• Clinicopathological assessment of cancer/testis antigens NY-ESO-1 and MAGE-A4 in osteosarcoma

  2022cites this paper
• Establishment and characterization of NCC-SS4-C1: a novel patient-derived cell line of synovial sarcoma

  2021cites this paper
• Immune and Cell Cycle Checkpoint Inhibitors for Cancer Immunotherapy

  2021cites this paper
• Targeted Therapies and Checkpoint Inhibitors in Sarcoma.

  2021cites this paper
• TCR Redirected T Cells for Cancer Treatment: Achievements, Hurdles, and Goals

  2020cites this paper
• Immunopathology of Bone and Connective Tissue Cancers and Immunotherapy of Sarcomas

  2020cites this paper
• The programmed cell death protein-1/programmed cell death ligand 1 expression, CD3+ T cell infiltration, NY-ESO-1 expression, and microsatellite instability phenotype in primary cutaneous melanoma and mucosal melanoma and their clinical significance and prognostic value: a study of 89 consecutive ca

  2020cites this paper
• Spinal Sarcomas and Immunity: An Undervalued Relationship.

  2020cites this paper
• Liposarcoma: Advances in Cellular and Molecular Genetics Alterations and Corresponding Clinical Treatment

  2020cites this paper
• Sarcomas - a barren immunological wasteland or field of opportunity for immunotherapy?

  2020cites this paper
• Systematic literature review of clinical outcomes in adults with metastatic or advanced synovial sarcoma.

  2020cites this paper
• Immunotherapy for synovial sarcoma

  2019cites this paper
• Synovial Sarcoma: Current Concepts and Future Perspectives.

  2018cites this paper
• Making progress in a rare disease: emerging therapeutics in soft tissue sarcomas

  2018cites this paper
• Sarcoma–The standard-bearer in cancer discovery

  2018cites this paper
• Immunotherapy: A New (and Old) Approach to Treatment of Soft Tissue and Bone Sarcomas.

  2018cites this paper
• Targeted Therapies in the Treatment of Sarcomas

  2018cites this paper
• PDL1 expression is a poor-prognosis factor in soft-tissue sarcomas

  2017cites this paper
• Metastatic biomarkers in synovial sarcoma

  2017cites this paper
• Targeted therapy for soft tissue sarcomas in adolescents and young adults

  2017cites this paper
• Translational research in diagnosis and management of soft tissue tumours

  2016cites this paper
• Current Immunotherapies for Sarcoma: Clinical Trials and Rationale

  2016cites this paper
• Immunotherapy of Childhood Sarcomas

  2015cites this paper
• Trial Watch: Peptide-based anticancer vaccines

  2015cites this paper
• Immunotherapeutic Approaches to Sarcoma

  2015cites this paper
• Application of serum NY-ESO-1 antibody assay for early SCLC diagnosis.

  2015cites this paper
• New York esophageal squamous cell carcinoma-1 and cancer immunotherapy.

  2015cites this paper
• A Novel Murine T-Cell Receptor Targeting NY-ESO-1

  2014cites this paper
• Trial Watch

  2014cites this paper
• Detection of cancer/testis antigens as a diagnostic tool in routine pathology practice

  2014cites this paper
• Trial Watch

  2014cites this paper
• Molecular Prognostic and Predictive Factors in Sarcomas

  2014cites this paper
• Trial Watch

  2013cites this paper
• Trial Watch

  2013cites this paper
• Trial watch

  2012cites this paper
• Testicular Synovial Sarcoma: A Case Report

  2012cites this paper